The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine
- 37 Downloads
The myelodysplastic syndromes (MDS) is a representative of myeloid clonal blood diseases with relatively heterogeneous spectrums of symptoms. The major clinical problem in MDS are morbidities caused by cytopenia or transition to acute myeloid leukemia (AML). The current clinical management of MDS focuses on assessing disease risk at diagnosis by assaying clinical and patient characteristics and using established prognostic scoring systems to estimate survival and risk of evolution to AML. Several prognostic scoring systems have been developed and validated, but the most widely used systems include the International Prognostic Scoring System (IPSS) and the Revised International Prognostic Scoring System (IPSS-R). Because the IPSS is limited in its ability to identify poor prognosis lower-risk patients, a prognostic scoring system specifically for lower-risk MDS patients (LR-PSS) was also developed at MD Anderson cancer center . Recently, several studies demonstrated...
No specific funding was obtained to support the conduct of this study.
Compliance with ethical standards
Conflict of interest
All authors have no potential conflicts of interest to report.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the patients. The study was approved by the Ethics Committee of Yokohama Municipal Citizen’s Hospital.